Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
7536285 | Revista Portuguesa de Cardiologia | 2017 | 4 Pages |
Abstract
Assessment of serum levels of natriuretic peptides, especially the aminoâterminal portion (NTâproBNP) and the carboxyâterminal portion (BNP) of proâBâtype natriuretic peptide, has had a highly significant clinical impact on the diagnosis and prognostic stratification of patients with heart failure (HF). They are now an instrument with recognized value in this context and several studies have demonstrated their value in tailoring therapy for these patients. Following the recent advent of angiotensin receptorâneprilysin inhibitors (ARNIs), there is a need to review how these two biomarkers are interpreted in HF. The use of ARNIs is associated with a reduction in NTâproBNP but an increase in BNP levels. The authors of this concise article review the interpretation of natriuretic peptide levels in the light of the most recent evidence.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Paulo Bettencourt, Cândida Fonseca, Fátima Franco, Aurora Andrade, Dulce Brito,